132691-38-4

Basic information

• Product Name: METHYL 2-(3-(N-BOC-AMINOMETHYL)PHENYL)ACETATE
• Synonyms: METHYL 2-(3-(N-BOC-AMINOMETHYL)PHENYL)ACETATE;TERT-BUTYL 3-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE;Methyl 2-(3-((tert-butoxycarbonylaMino)Methyl)phenyl)acetate
• CAS NO: 132691-38-4
• Molecular Formula: C₁₅H₂₁NO₄
• Molecular Weight: 279.34
• Mol File: 132691-38-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 400.1±33.0 °C(Predicted)
• Appearance: /
• Density: 1.102±0.06 g/cm3(Predicted)
• PKA: 12.14±0.46(Predicted)
• CAS DataBase Reference: METHYL 2-(3-(N-BOC-AMINOMETHYL)PHENYL)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-(3-(N-BOC-AMINOMETHYL)PHENYL)ACETATE(132691-38-4)
• EPA Substance Registry System: METHYL 2-(3-(N-BOC-AMINOMETHYL)PHENYL)ACETATE(132691-38-4)

Safety Data

• Hazardous Substances Data: 132691-38-4(Hazardous Substances Data)

Upstream product

• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 52798-00-2 (3-cyano-phenyl)-acetic acid methyl ester 
• 1878-67-7 3-Bromophenylacetic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 754959-55-2 methyl 2-(3-(aminomethyl)phenyl)acetate 

Downstream Products

• 71420-95-6 2-(3-(((tertbutoxycarbonyl)amino)methyl)phenyl)acetic acid 
• 808753-19-7 2-(3-aminomethyl-phenyl)-N-methyl-N-(1-phenyl-2-pyrrolidin-1-yl-ethyl)-acetamide 
• 808753-16-4 [3-({methyl-[1-(S)-phenyl-2-pyrrolidin-1-yl-ethyl]-carbamoyl}-methyl)-benzyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

COMPOUNDS AND THEIR METHODS OF USE

Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.

COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds of formula (I), which can inhibit glutaminase. Pharmaceutical compositions comprising these compounds and uses as glutaminase inhibitors for treating cancers thereof are also provided.

Sulfonylamino phenylacetamide derivatives and methods of their use

Sulfonylamino phenylacetamide derivatives of the general formula are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed. In certain embodiments, the compounds of the invention that, preferably: (1) bind with high affinity to κ opioid receptors; (2) display good opioid receptor selectivity of κ versus μ and κ versus δ; and (3) do not substantially inhibit cytochrome P450 enzymatic activity, in particular CYP2D6, CYP2C9 and CYP3A4.